Those are the right numbers for TSRX - pulled from their financials. I'm involved in investing in (err, trading) drug stocks, and we owned TSRX during most of that period, they didn't have any major R&D expense off the income statement.
Yes, but it's just a derivative of an already existing class. That's not particularly useful as it's based off a 2002 compound from AZ.
I mean
novel as in
novel mechanism of action.
Anyone can make an analogue of an already existing family.
edit: I do like Cubist as a company though.